JP2024511853A5 - - Google Patents
Info
- Publication number
- JP2024511853A5 JP2024511853A5 JP2023560403A JP2023560403A JP2024511853A5 JP 2024511853 A5 JP2024511853 A5 JP 2024511853A5 JP 2023560403 A JP2023560403 A JP 2023560403A JP 2023560403 A JP2023560403 A JP 2023560403A JP 2024511853 A5 JP2024511853 A5 JP 2024511853A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- domain
- queel
- amino acid
- gfral
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2104556.2A GB202104556D0 (en) | 2021-03-31 | 2021-03-31 | Therapeutic inhibitors of GDF15 signalling |
| GB2104556.2 | 2021-03-31 | ||
| GB2107331.7 | 2021-05-21 | ||
| GBGB2107331.7A GB202107331D0 (en) | 2021-05-21 | 2021-05-21 | Therapeutic inhibitors of GDF15 signalling |
| GBGB2108170.8A GB202108170D0 (en) | 2021-06-08 | 2021-06-08 | Theraputic inhibitors of GDF15 Signalling |
| GB2108170.8 | 2021-06-08 | ||
| PCT/EP2022/058669 WO2022207846A1 (en) | 2021-03-31 | 2022-03-31 | Therapeutic inhibitors of gdf15 signalling |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024511853A JP2024511853A (ja) | 2024-03-15 |
| JP2024511853A5 true JP2024511853A5 (enExample) | 2025-04-07 |
Family
ID=81580347
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023560403A Pending JP2024511853A (ja) | 2021-03-31 | 2022-03-31 | Ｇｄｆ１５シグナル伝達の治療的阻害剤 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20240182585A1 (enExample) |
| EP (1) | EP4314071A1 (enExample) |
| JP (1) | JP2024511853A (enExample) |
| KR (1) | KR20230165285A (enExample) |
| AU (1) | AU2022251923A1 (enExample) |
| BR (1) | BR112023020152A2 (enExample) |
| CA (1) | CA3215737A1 (enExample) |
| CO (1) | CO2023013791A2 (enExample) |
| IL (1) | IL307382A (enExample) |
| MX (1) | MX2023011655A (enExample) |
| WO (1) | WO2022207846A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2017172260A1 (en) | 2016-03-31 | 2017-10-05 | Ngm Bioparmaceuticals, Inc. | Binding proteins and methods of use thereof |
| IT202300006387A1 (it) * | 2023-03-31 | 2024-10-01 | Univ Degli Studi Roma La Sapienza | Inibitore del recettore gfral per uso nel trattamento della sclerosi laterale amiotrofica |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
| US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
| JP4336498B2 (ja) | 2000-12-12 | 2009-09-30 | メディミューン，エルエルシー | 延長した半減期を有する分子ならびにその組成物および用途 |
| US20050266425A1 (en) | 2003-12-31 | 2005-12-01 | Vaccinex, Inc. | Methods for producing and identifying multispecific antibodies |
| ES2518865T3 (es) | 2004-04-13 | 2014-11-05 | St Vincent's Hospital Sydney Limited | Agente de inhibición de MIC-1 |
| JOP20080381B1 (ar) | 2007-08-23 | 2023-03-28 | Amgen Inc | بروتينات مرتبطة بمولدات مضادات تتفاعل مع بروبروتين كونفيرتاز سيتيليزين ككسين من النوع 9 (pcsk9) |
| CA2783934A1 (en) | 2009-12-11 | 2011-06-16 | Genecode As | Methods of facilitating neural cell survival using gdnf family ligand (gfl) mimetics or ret signaling pathway activators |
| WO2013012648A1 (en) | 2011-07-15 | 2013-01-24 | Emory University | Gdf15 in diagnostic and therapeutic applications |
| CN102321173B (zh) | 2011-08-12 | 2013-04-03 | 中国医学科学院肿瘤研究所 | 人源化巨噬细胞抑制因子1单克隆抗体及其应用 |
| PT2900263T (pt) | 2012-09-26 | 2019-07-29 | Univ Wuerzburg J Maximilians | Anticorpos monoclonais contra o factor de crescimento e diferenciaçao 15 (gdf-15) |
| CA2896076C (en) | 2012-12-21 | 2022-12-06 | Aveo Pharmaceuticals, Inc. | Anti-gdf15 antibodies |
| EP3122775B1 (en) | 2014-03-26 | 2019-11-13 | Julius-Maximilians-Universität Würzburg | Monoclonal antibodies to growth and differentiation factor 15 (gdf-15), and uses thereof for treating cancer cachexia and cancer |
| HUE054670T2 (hu) | 2014-09-25 | 2021-09-28 | Aveo Pharmaceuticals Inc | Módszer cachexia visszafordítására és túlélés megnövelésére egy GDF15 modulátor és egy rákellenes szer adagolásával |
| JP6925326B2 (ja) | 2015-10-02 | 2021-08-25 | ユリウス−マクシミリアン−ウニヴェルシテート・ヴュルツブルク | ヒト成長分化因子１５（ｇｄｆ−１５）の阻害剤及び免疫チェックポイントブロッカーを使用する併用療法 |
| WO2017121865A1 (en) | 2016-01-15 | 2017-07-20 | Novo Nordisk A/S | Mic-1 receptor and uses thereof |
| JP2019510739A (ja) * | 2016-02-29 | 2019-04-18 | イーライ リリー アンド カンパニー | Ｇｆｒａｌ受容体療法 |
| AU2017228489A1 (en) | 2016-03-04 | 2018-09-06 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for modulating body weight |
| WO2017172260A1 (en) | 2016-03-31 | 2017-10-05 | Ngm Bioparmaceuticals, Inc. | Binding proteins and methods of use thereof |
| CN109071647B (zh) | 2016-04-27 | 2022-11-22 | 诺华股份有限公司 | 抗生长分化因子15的抗体及其用途 |
-
2022
- 2022-03-31 EP EP22720935.0A patent/EP4314071A1/en active Pending
- 2022-03-31 IL IL307382A patent/IL307382A/en unknown
- 2022-03-31 CA CA3215737A patent/CA3215737A1/en active Pending
- 2022-03-31 MX MX2023011655A patent/MX2023011655A/es unknown
- 2022-03-31 KR KR1020237037287A patent/KR20230165285A/ko active Pending
- 2022-03-31 WO PCT/EP2022/058669 patent/WO2022207846A1/en not_active Ceased
- 2022-03-31 BR BR112023020152A patent/BR112023020152A2/pt unknown
- 2022-03-31 US US18/284,952 patent/US20240182585A1/en active Pending
- 2022-03-31 JP JP2023560403A patent/JP2024511853A/ja active Pending
- 2022-03-31 AU AU2022251923A patent/AU2022251923A1/en active Pending
-
2023
- 2023-10-19 CO CONC2023/0013791A patent/CO2023013791A2/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7682335B2 (ja) | オンコスタチンｍ受容体抗原結合タンパク質 | |
| JP7665098B2 (ja) | 多重特異性抗体およびその使用 | |
| JP2018521691A5 (enExample) | ||
| US12194095B2 (en) | Combinations and uses thereof | |
| BR112021008288A2 (pt) | composição farmacêutica de proteína de fusão do receptor tgf-ss e uso da mesma | |
| RU2018106364A (ru) | Антитела против рецептора tfr и их применение при лечении пролиферативных и воспалительных расстройств | |
| JP2016538876A5 (enExample) | ||
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение | |
| KR20160062167A (ko) | 죽상경화증의 치료를 위한 세마포린-4d 결합 분자의 용도 | |
| RU2014139552A (ru) | Человеческие антитела к токсинам clostridium difficile | |
| JP2015503909A5 (enExample) | ||
| KR102500868B1 (ko) | 항-cd19 항체 및 bcl-2 억제제의 조합 및 이의 용도 | |
| WO2012098238A1 (en) | Combination therapies and methods using anti-cd3 modulating agents and anti-il-6 antagonists | |
| KR20160135835A (ko) | 인간 카나비노이드 1(cb1) 수용체 결합 항체 | |
| JP2020522280A5 (enExample) | ||
| JP2022544050A5 (enExample) | ||
| TW202108631A (zh) | 一種抗ｃｄ４７抗原結合蛋白及其應用 | |
| JP2022527542A5 (enExample) | ||
| JP2024505195A5 (enExample) | ||
| JP2024502670A5 (enExample) | ||
| JP7668943B2 (ja) | 多重特異性抗体およびその使用 | |
| CN114316046B (zh) | 一种稳定的抗体组合物 | |
| JP2022537142A5 (enExample) | ||
| JP2025539796A (ja) | Ｌａｇ－３およびｐｄ－１／ｌａｇ－３抗体 | |
| AU2023355736A1 (en) | Combination of a btn3a activating antibody, a bcl2 inhibitor and hypomethylating agent for use in treating cancer |